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F
ebrile neutropenia is a syndrome defined by the presence of fever (single oral tempera-
ture = 38,30C or >38 0C for = 1h) in a cancer patient with neutropenia (neutrophil
count fewer than 0.5 x 109 /l, or fewer than 1.0 x 109 /l but predicted to decline to fewer
than 0.5 x 109 /l over the next 48h), (1). Fever should not be caused by noninfectious caus-
es such as cancer itself, drugs, blood product transfusion or graft versus host disease
(GVHD).  Febrile neutropenia is a syndrome we have created with cancer treatments
(chemotherapy and/or radiotherapy).
BACKGROUND (1-3)
Infection is the main cause of fever in neutropenic cancer patient. Consequently, any fever
that develops during the episode of neutropenia should be considered to be due to infection
until proven otherwise. The frequency and severity of infection is primarily related to the
depth and duration of neutropenia. Although the risk of infection is present when neutrophil
count is below 1 x 109/l, it is really increased if neutrophil count is lower than 0.5 x 109/l
("standard" neutropenia). The risks of severe infection and bacteremia are greatest when
neutrophil count falls below 0.1 x 109/l ("profound" neutropenia). Besides initial depth of
neutropenia the duration of neutropenia is also critical for clinical outcome during febrile
neutropenic episode: neutropenia lasting for more than 7 days is considered a "high risk"
neutropenia. Neutropenia markedly alters the inflammatory response, making it difficult to
detect the presence of infection. Fever is the earliest and commonly the only sign of an
infection, other signs and symptoms being minimal or frequently absent. Since undetected
and untreated infections can progress quickly in neutropenic patients, neutropenic fever
should be considered a medical emergency. The most common sites of infection in neu-
tropenic cancer patient are alimentary tract (i.e., mouth, pharynx, lower esophagus); lungs;
perineum, including anus; and skin. Bacteria are responsible for the majority of initial infec-
tions. Until two decades ago, gram-negative bacilli, especially Pseudomonas aeruginosa,
Escherichia coli, and Klebsiella species were the predominant bacteremic isolates.
Nowadays, bacteremia is most frequently due to gram-positive bacteria, namely coagulase-
negative staphylococci, Staphylococcus aureus, viridans group of streptococci and entero-
cocci. Even if they become less frequent, gram-negative infections remain of major concern
to clinicians since their mortality in neutropenic patients is still high and their course can be
fulminant. Subsequent infections of the neutropenic patient are usually caused by fungi
(mainly Candida and Aspergillus species) and viruses but also by antibiotic-resistant bac-
teria.   Based both on the clinical course and microbiological data each febrile neutropenic
episode is retrospectively classified as: (1) microbiologically documented infection, (2)
clinically documented infection, or (3) infection without any microbiological or clinical doc-
umentation ("fever of unknown etiology").
EVALUATION (1,3,4)
Initial evaluation of febrile neutropenic patient is aimed at determining the potential sites of
infection and causative organisms. Initial evaluation encompasses site-specific history;
scrupulous physical examination; laboratory evaluation (a complete blood cell count, meas-
urement of serum levels of creatinine, urea nitrogen, and transaminases); culture of blood
samples; a chest radiograph for patients with respiratory signs and symptoms; as well as
site-specific cultures and imaging studies (if signs and symptoms point to a specific site).
In addition, the assessment of a risk for serious medical complications during the episode
of febrile neutropenia should be performed. Recently a scoring system to identify, at the
onset of febrile neutropenia, patients with a low risk for serious medical complications was
developed and validated by MASCC (Multinational Association for Supportive Care in
Cancer) Study Section of Infectious Diseases (MASCC score) (4).
This score allows us to split febrile neutropenic patients into low- and high-risk on the basis
of the criteria easily assessable at the time of presentation: age, underlying malignancy in
interaction with a history of fungal infection, inpatient status, burden of symptoms, pres-
ence of hypotension, of chronic obstructive disease or of dehydration. Carefully selected
patients with a low risk for developing serious medical complications during the episode of
febrile neutropenia are candidates for initial treatment outside traditional hospital setting oran empiric therapy with oral antibiotics. 
MANAGEMENT (1,3,5)
All neutropenic cancer patients should be considered to be at risk for infection and, once
febrile, should be treated immediately with antimicrobials, without waiting for clinical and/or
microbiological documentation of infection ("empirical antibiotic therapy"). In addition,
afebrile patients who are neutropenic and have signs and symptoms suggesting an infec-
tion should also receive empirical antibiotic therapy. 
Available clinical practice guidelines (CPGs) for the use of antimicrobial agents in neu-
tropenic patients with cancer state that "no specific scheme, no specific drug or combina-
tion of drugs, and no specific period of treatment can be unequivocally applied to all febrile
neutropenic patients". 
Treatment with intravenous antibiotics
Traditional management of febrile neutropenic patients consists of hospitalization and treat-
ment with intravenous, bactericidal, broad-spectrum antibiotics. Three antibiotic regimens
for empirical treatment are equally recommended: (1) dual therapy with aminoglycoside in
combination with antipseudomonal penicillin (ticarcillin-clavulanic acid, piperacillin-
tazobactam); or with an extended spectrum antipseudomonal cephalosporin (cefepime,
ceftazidime); or with a carbapenem (imipenem/cilastatin, meropenem); (2) monotherapy
with carbapenem, cefepime, ceftazidime or piperacillin/tazobactam, and (3) the combina-
tion of dual therapy or monotherapy with vancomycin for specific indications.
Advantages of duo therapy with an aminoglycoside are broad coverage, potential syner-
gistic effects against gram-negative bacilli and protection of the patient, in case the infect-
ing organism is resistant to one of the empirically administered drugs (usually beta-lactam).
Dual therapy with aminoglycoside is recommended for patients with a history of P. aerug-
inosa colonization or invasive disease. The major disadvantages are the lack of activity
against some gram-positive bacteria (now predominant), and the nephrotoxicity, ototoxici-
ty, and hypokaliemia associated with the use of amynoglycosides. More recently, there is
a trend towards monotherapy of febrile neutropenia with carbapenems, cefepime, cef-
tazidime or piperacillin/tazobactam. In fact, most patients with solid tumors can be safely
and effectively treated with monotherapy, and certainly those who are clinically stable with
"standard" neutropenia and expected duration of further neutropenia less than 7-10 days.
Patient should be closely monitored for no response: modifications of the initial monother-
apy regimen may be necessary according to clinical  / microbiological data. The increased
frequency of beta-lactam resistant gram-positive pathogens and the fulminant clinical
course of certain gram-positive infections made the rationale for the inclusion of van-
comycin into empirical antibiotic regimen. Nevertheless, clinical trials have shown that van-
comycin is not a necessary part of the initial empirical regimen. Empiric use of vancomycin
is justified only in patients at high risk for serious gram-positive infections in following clin-
ical situations: clinically documented serious catheter-related infection; substantial mucos-
al damage; prophylaxis with TMP-SMZ or quinolone antibiotics; known colonization with
penicillin and cephalosporin resistant pneumococci or meticillin-resistant S. aureus; blood
culture positive for gram-positive bacteria; and hypotension or septic shock without an
identified pathogen. 
To conclude, many antibiotic regimens are effective for initial, empirical treatment of pre-
sumed infection in patients with febrile neutropenia. The following factors can assist clini-
cians in antibiotic selection: local epidemiological situation (local patterns of infection and
susceptibility of local bacterial isolates), patient clinical condition at the onset of fever, the
risk for developing infection-related, serious medical complications, previous antibiotic
therapy, patient medication allergy, as well as preexisting organ dysfunction. 
Treatment with oral antibiotics
Carefully selected patients, determined to be at a low risk for developing infection-related
complications during the course of neutropenia (see above) may be treated with oral antibi-
otic therapy as an alternative for intravenous monotherapy. Oral antibiotic are as safe as
standard intravenous approach in terms of success rate and complications development at
least when patients are managed in a hospital setting. The reference regimen is a combi-
nation of oral ciprofloxacin plus amoxicillin-clavulanate. For patients who are allergic to
penicillin, the combination of oral clindamicin with oral ciprofloxacin is recommended.
Use of hematopoietic colony-stimulating factors
Colony stimulating factors are not recommended for routine use to treat febrile or afebrile
neutropenic patients. The use of colony stimulating factors in neutropenic cancer patients
should be guided by the recommendations given in the valid CPGs (5). 
MONITORING (1,3)
Daily evaluation of febrile neutropenic patient is essential. In general, it includes site-spe-
cific history and examination, review of all previous culture, laboratory and imaging results,
culturing of additional blood samples and specimens of specific sites of infection and diag-
nostic imaging of any organ suspected of having an infection. At least 3 to 5 days of antibi-
otic treatment are usually required to determine efficacy of the initial regimen. From this
point, in general, further management is dictated by the patient’s clinical condition, new
clinical and /or microbiologic findings identifying the site of infection and /or the causative
pathogen (patients with clinically or microbiologically documented infection versus patients
with fever of unknown etiology), fever response to antibiotic treatment (patients afebrile
within first 3-5 days of treatment versus patients with persistent fever), along with the
recovery of neutrophils. The treatment with vancomycin should be considered if clinical or
microbiological findings supporting its use are met (see above). The initiation of empiric
antifungal therapy is warranted in neutropenic patient who remains febrile after 5-7 days of
broad-spectrum antibiotics (persistent or recurrent fever), in whom no bacterial infection
can be documented, and neutropenia is expected to last for longer than 5-7 more days.
Amphothericin B deoxycholate has traditionally been the drug of choice, however, clinical
studies also support the use of less toxic alternatives such as lipid formulations of ampho-
tericin B, fluconasole, itraconazole, voriconazole, and caspofungin.  
No specific period of treatment can be unequivocally recommended for all febrile neu-
tropenic patients. The most important determinants of the duration of treatment are the doc-
umentation of infection and recovery of patient’s neutrophil count. Recommendations for
determining the duration of antibiotic treatment under various clinical conditions in patients
with febrile neutropenia are provided in valid CPGs (1,3). 
PREVENTION OF INFECTION (1,3)
The routine prophylaxis with antibacterial (TMP-SMZ or quinolones), antifungal (flucona-
zole, itraconazole) or with antiviral drugs in all afebrile neutropenic patients is not recom-
mended.
In conclusion, febrile neutropenia has been a changing syndrome over past years. Empirical
antibiotic treatment of all neutropenic patients at the onset of fever remains the cornerstone
of infection management. The specific composition of the empirical antibiotic regimen
remains subject to change, due to changing pattern of pathogens, the emergence of antibi-
otic-resistant organisms, the appearance of the new clinical entities, the availability of new
drugs and the improved models for patient’s infection risk categorization. No specific antibi-
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all febrile neutropenic patients. Evidence based clinical practice guidelines related to the
management of febrile neutropenia are developed to assist practitioners and patients in their
decision making (1,3,6,7).
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